

# One year results of the Association of British Clinical Diabetologists (ABCD) sponsored Endobarrier in type 2 diabetes/pre-diabetes with Obstructive sleep apnoea(OSA) study

M Yadagiri(1), F Kinney(2), J Adams(3), A Mohammed(3), JP Bleasdale(4), EN Fogden(5), MR Anderson(5), M Greenstone(6), C Walton(7), REJ Ryder(1)

(1) Diabetes Department, Sandwell and West Birmingham Hospital NHS Trust, Birmingham, (2) Research and Development, Sandwell and West Birmingham Hospital NHS Trust, Birmingham, (3) Respiratory Physiology, Sandwell and West Birmingham Hospital NHS Trust, Birmingham, (4) Anaesthetics Department, Sandwell and West Birmingham Hospital NHS Trust, Birmingham, (5) Gastroenterology, Sandwell and West Birmingham Hospital NHS Trust, Birmingham, (6) Respiratory Department, Castle Hill Hospital, Cottingham, (7) Diabetes Department, Hull Royal Infirmary, Hull.

## Background

Obstructive sleep apnoea(OSA) is associated with obesity and any weight loss is known to improve OSA. Type 2 diabetes and OSA requiring continuous positive airway pressure(CPAP) are associated with obesity and independently associated with increased cardiovascular risk. Sometimes both conditions coincide in the same patient with, therefore, especially high cardiovascular risk.

Endobarrier is a relatively new device which has been proven to reduce weight and improve diabetes control in previous research trials. The Endobarrier is a 60cm long tube-like structure (open at both ends) composed of a fluoropolymer flexible wall and a crown-shaped anchor composed of a nickel-titanium alloy at one end. It is an endoscopically inserted device which is deployed in the small intestine (just beyond the stomach) and removed up to 1 year later.

## End OSA Trial

End-OSA trial (ISRCTN:33788132) is an NIHR sponsored research trial, to investigate to what extent does the weight loss associated with Endobarrier treatment improve the indices of OSA in patients with diabetes treated with CPAP(continuous positive airway pressure).



It is a response to intervention trial involving 12 subjects with study duration of 24 months including patients with moderate OSA (Apnoea Hypopnea Index 15-29 events/hr) treated with CPAP, type 2 diabetes or prediabetes, obesity(BMI between  $\geq 30$  and  $\leq 45$  kg/m<sup>2</sup>) and age  $\geq 18$  years.

This ongoing study participants are recruited from Birmingham's City Hospital sleep service clinic and all the clinic visits, blood tests as well as sleep studies are done at the same centre.

## Baseline Characteristics




	n(12)
Age(years)	52.6±9.7
Sex(%)	Females(75%)
Ethnicity(%)	Caucasian(50%)
T2DM pt's (n)	8(66%)
Pre-diabetes pt's (n)	4(33%)
Mean Wt(kg)	103.8±14.1
Mean BMI(Kg/m <sup>2</sup> )	37.4±3.5
Mean HbA1c (mmol)	62.5±17.4
Mean AHI (events/hr)	18.8±3.8
Duration of OSA {Median(IQR)years}	1.5(1.0-2.4)

## Endobarrier



## Results

We report here the results on all 12 participants who have reached at least 12 months of Endobarrier treatment. At Endobarrier removal, the mean  $\pm$  SD weight fell by  $10.5 \pm 4.0$ kg from  $103.8 \pm 14.1$  to  $93.3 \pm 13.8$ kg ( $p < 0.001$ ),



mean BMI by  $3.8 \pm 1.6$ kg/m<sup>2</sup> from  $37.4 \pm 3.5$  to  $33.5 \pm 3.3$ kg/m<sup>2</sup> ( $p < 0.001$ ), mean HbA1c by  $13.6 \pm 17.8$ mmol/mol from  $62.5 \pm 17.4$  to  $48.8 \pm 10.6$ mmol/mol ( $p = 0.023$ ). In the follow up overnight sleep studies, twelve months after Endobarrier treatment, mean AHI(Apnoea Hypopnea Index) fell from  $18.8 \pm 3.8$  to  $11.3 \pm 4.8$  events/hour ( $p = 0.002$ ).

Prior to Endobarrier, all 12 patients had AHI in moderate sleep apnoea range (15–29.9 events/hour). But following Endobarrier treatment, the AHI of 10/12(83%) patients fell below the moderate sleep apnoea threshold of 15 events/hour, such that they no longer required CPAP, according to NICE guidelines. Of the remaining 2 patients, one came off CPAP completely at 18 months and the other transiently at 9 months. One of the participants had an SAE in the form of a small perforation of oesophagus during Endobarrier removal which was conservatively managed.

## Conclusion

These one year results are encouraging in that Endobarrier has already allowed 11/12(91%) patients to discontinue CPAP, in addition to glycaemic and weight benefits. Discontinuing CPAP is beneficial to health services but especially to patients. As endoscopy units are ubiquitous, Endobarrier treatment could be readily disseminated all over the NHS.